Studies have shown that an elevated proportion of CX3CR1+ subpopulations within circulating CD8+ T cells at an early stage following anti-PD-1 therapy correlates with a favorable response and improved survival in patients with NSCLC (31). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.